Push for Inflectra pharmacovigilance program

The Australian Rheumatology Association has called for a pharmacovigilance program to be set up for biosimilar Inflectra amid lingering concerns about whether switching is safe.

The Federal Department of Health has released an updated biosimilar framework saying they are still in discussions with the ARA to establish a “data collection ability” for the prescription of Inflectra.